Non targeted novel fusions were also identified including FGFR1-NRG1 in breast, BRAF-MRPS33 in prostate, SND1-MET in lung, PCM1-BRAF in sarcoma and TMEM178B-MET in rectal cancer. Here, MET is linked to rectal cancer.